DASH: Dysvascular Amputation Self-Management of Health

Sponsor
University of Colorado, Denver (Other)
Overall Status
Recruiting
CT.gov ID
NCT04083456
Collaborator
National Institute of Nursing Research (NINR) (NIH)
64
1
2
52
1.2

Study Details

Study Description

Brief Summary

The purpose of this study is to determine if walking biobehavioral intervention improves physical activity after dysvascular lower limb amputation.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Walking Biobehavioral Intervention
  • Other: Attention Control
N/A

Detailed Description

Sedentary lifestyles and high levels of disability are relevant public and personal health issues resulting from the chronic comorbid condition of dysvascular lower limb amputation. This study examines the use of an evidence-based walking biobehavioral intervention to increase physical activity after dysvascular amputation. The proposed intervention leverages successes in conventional prosthetic rehabilitation, while addressing the complex health conditions and chronic sedentary behaviors that underlie dysvascular amputation, with the ultimate goal of improved physical activity self-management to minimize disability.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
64 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled futility designRandomized controlled futility design
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Improving Health Self-Management Using Walking Biobehavioral Intervention for People With Dysvascular Lower Limb Amputation
Actual Study Start Date :
Nov 1, 2019
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Walking Biobehavioral Intervention (EXP)

The EXP group will receive biobehavioral training that is integrated into the conventional outpatient training component and is delivered over 5 months. There will be 10 biobehavioral sessions, 1 of which will be a combined biobehavioral/conventional outpatient session and the other 9 being telehealth sessions.

Behavioral: Walking Biobehavioral Intervention
Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.

Active Comparator: Attention Control (CTL)

The CTL group intervention will include the same conventional outpatient training (10 sessions) as the EXP group and receive the same computer tablets with telehealth software as the EXP group (week 3 of prosthetic training).

Other: Attention Control
Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.

Outcome Measures

Primary Outcome Measures

  1. Physical Activity [Day 0 (start of conventional prosthetic rehabilitation), prosthetic rehabilitation end (3 months), intervention end (6 months), and 6 months after intervention end (12 months)]

    Change in 10 day physical activity step count with ActivPAL activity monitor between the beginning of conventional prosthetic rehabilitation to the end of intervention. Maintenance will be observed at six months after the end of the intervention.

Secondary Outcome Measures

  1. Patient Reported Outcomes Measurement Information System (PROMIS): Self-Efficacy for Managing Symptoms [Day 0, 3 months, 6 months and 12 months]

    Change in participant's confidence in managing symptoms of chronic disease. Final scores range from 4 points (not at all confident) to 20 points (very confident).

  2. PROMIS: Self-Efficacy for Managing Daily Activities [Day 0, 3 months, 6 months and 12 months]

    Change in participant's confidence in managing daily activities. Final scores range from 4 points (not at all confident) to 20 points (very confident).

  3. PROMIS: Ability to participate in social roles and activities [Day 0, 3 months, 6 months and 12 months]

    Change in participant's ability to participate in social roles and activities. Final scores range from 8 points (never participates) to 40 points (always participates).

  4. Prosthesis Evaluation Questionnaire - Mobility Score [Day 0, 3 months, 6 months and 12 months]

    Change in self-reported mobility. Final scores range from 0 (lowest mobility) to 4 (highest mobility)

  5. Timed Up-and-Go test [Day 0, 3 months, 6 months and 12 months]

    Change in time required to rise from chair, walk 10 feet, turn around and return to sitting in same chair.

  6. World Health Organization-Disability Assessment Schedule 2.0 [Day 0, 3 months, 6 months and 12 months]

    Change in self-reported disability. Final scores range from 0 (no disability) to 100 (full disability).

  7. Self-Efficacy for Managing Chronic Disease [Day 0, 3 months, 6 months and 12 months]

    Change in self-reported confidence in managing different aspects of chronic disease. Final scores range from 1 (not at all confident in managing chronic disease) to 10 (totally confident in managing chronic disease).

Other Outcome Measures

  1. Activities-specific Balance Confidence Scale [Day 0, 3 months, 6 months and 12 months]

    Change in self-reported balance confidence. Final scores range from 0% (no confidence in balance) to 100% (complete confidence in balance).

  2. Two-Minute Walk Test [Day 0, 3 months, 6 months and 12 months]

    Change in the distance a participant can walk in two minutes. Use of assistive device is noted

  3. Five Meter Walk [Day 0, 3 months, 6 months and 12 months]

    Change in the length of time it takes a participant to walk 5 meters, at a comfortable walking pace.

  4. Study Intervention Reach [Day 0]

    Percentage of eligible participants enrolled

  5. Outpatient Practitioner Intervention Fidelity [Day 0 through 3 months]

    An individual practitioner's percent adherence to outpatient intervention protocol

  6. Biobehavioral Practitioner Intervention Fidelity [Day 0 through 6 months]

    An individual interventionist's percent adherence to biobehavioral intervention protocol

  7. FitBit Use Adherence [Month 12]

    Number of days participant uses FitBit during the no-contact phase of the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Within the age range of 50-85 years

  • Confirmed diagnosis of Type II Diabetes Mellitus (DM) and/or Peripheral Artery Disease (PAD)

  • Transtibial, knee disarticulation, or transfemoral lower-limb amputation (LLA) (or re-amputation) within the past 12 months

  • Participant goal of household walking or better using a prosthesis

Exclusion Criteria:
  • Trauma or cancer-related etiology of the LLA

  • Decisionally challenged individuals (MMSE score below 24)

  • Prisoners

  • Active cancer treatment

  • Recent stroke (within 2 years)

  • Clinical discretion of principal investigator to exclude patients who are determined to be unsafe and/or inappropriate to participate in the described intervention.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Colorado Hospital Aurora Colorado United States 80045

Sponsors and Collaborators

  • University of Colorado, Denver
  • National Institute of Nursing Research (NINR)

Investigators

  • Principal Investigator: Cory Christiansen, PT, PhD, University of Colorado, Denver

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT04083456
Other Study ID Numbers:
  • 19-0534
  • R01NR018450
First Posted:
Sep 10, 2019
Last Update Posted:
Apr 15, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Colorado, Denver
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 15, 2022